Clinical trials: Cancer Patient
Prostate Cancer, Hormone Refractory Prostate Cancer
A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer
This is a multi-center open-label dose-escalation study of a novel compound (MDV3100) to treat patients with castration-resistant (hormone-refractory) prostate cancer.
- Trial name
- NCT00510718
- Testing
- MDV3100
- Where
- 9 sites in United States
- Volunteers
- 140 people
- Sponsor
- Pfizer
Adenocarcinoma of the Stomach, Gastroesophageal Junction Expressing Guanylyl Cyclase C
A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophageal Junction
The purpose of this study is to assess the efficacy, safety and tolerability of MLN0264 in patients with recurrent or metastatic guanylyl cyclase C (GCC)-positive adenocarcinoma of the stomach or gastroesophageal junction.
- Trial name
- NCT02202759
- Testing
- MLN0264
- Where
- 17 sites in United States, Belgium and 2 more
- Volunteers
- 38 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Primary Peritoneal Cancer, Advanced Epithelial Ovarian Cancer
Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
The goal of this study was to determine the efficacy of iniparib (BSI-201/SAR240550) in patients with breast cancer gene-associated (BRCA) ovarian cancer.
- Trial name
- NCT00677079
- Testing
- Iniparib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Sanofi
Malignant Melanoma
Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)
The primary objective for this non-interventional study was to assess the quality of life of melanoma patients under adjuvant treatment with dabrafenib and trametinib in real world setting in Portugal through disease specific…
- Trial name
- NCT04547946
- Testing
- dabrafenib + trametinib
- Where
- 2 sites in Portugal
- Volunteers
- 3 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumor
Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)
This study will evaluate the safety and clinical activity of MRTX849 (adagrasib) in combination with palbociclib in patients with advanced solid tumor malignancies with KRAS G12C mutation.
- Trial name
- NCT05178888
- Testing
- MRTX849, Palbociclib
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- Mirati Therapeutics Inc.
Solid Tumor, Hematological Malignancy
A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies
The purpose of this study is to evaluate the plasma concentration and pharmacodynamics effects of warfarin 5 mg, in the presence or absence of belinostat 1,000 mg/m².
- Trial name
- NCT01317927
- Testing
- Belinostat, Warfarin
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Plasma Cell Myeloma
Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation
Primary Objectives: VCDI cohort: To determine the maximum tolerated dose (MTD) and recommended dose (RD) of SAR650984 isatuximab when administered in combination with bortezomib (Velcade®) , cyclophosphamide, and dexamethasone…
- Trial name
- NCT02513186
- Testing
- lenalidomide, bortezomib, cyclophosphamide
- Where
- 12 sites in France, Germany and 2 more
- Volunteers
- 90 people
- Sponsor
- Sanofi
Non-Small-Cell Lung Cancer, Pleural Effusion, Malignant
Non-small Cell Lung Cancer Registry
This trial will evaluate two separate groups of patients with stage IIIB/IV non-small cell lung cancer. The objective of Group 1 is to investigate an FDA-approved drug in stage IIIB/IV non-small cell lung cancer patients that has…
- Trial name
- NCT00099541
- Testing
- zoledronic acid
- Where
- 101 sites in United States
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Relapsed/Refractory Small Cell Lung Cancer
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
The main aim of this study is to: evaluate safety and efficacy (per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1] by investigator) of 2 dose levels of tarlatamab for Part 1 only evaluate anti-tumor…
- Trial name
- DeLLphi-301 (NCT05060016)
- Testing
- Tarlatamab
- Where
- 80 sites in United States, Austria and 16 more
- Volunteers
- 222 people
- Sponsor
- Amgen
Multiple Myeloma
Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma
This is a Phase I/IIa clinical trial to identify the maximum tolerated dose of atiprimod and to evaluate the safety of atiprimod in patients with refractory or relapsed multiple myeloma.
- Trial name
- NCT00086216
- Testing
- Atiprimod
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Callisto Pharmaceuticals
Advanced Solid Tumor
A Study of HS269 in Patients With Advanced Solid Tumors
This is a Phase I, open-label, first in human study of HS269 tablet, a small molecule highly-selective RET Inhibitor. The dose-escalation study will assess the safety, tolerability, and pharmacokinetics of HS269 and determine the…
- Trial name
- NCT05058352
- Testing
- HS269
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
Pain, Cancer
Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients
The purpose of this study is to evaluate the long-term safety and effectiveness of EN3267 in treating breakthrough pain episodes in opioid cancer patients who are using stable doses of opioid medication.
- Trial name
- NCT00263575
- Testing
- EN3267
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug[s]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab.
- Trial name
- NCT03972657
- Testing
- REGN5678, Cemiplimab
- Where
- 26 sites in United States, South Korea
- Volunteers
- 345 people
- Sponsor
- Regeneron Pharmaceuticals
Non-Hodgkin Lymphoma
EMD 521873 in Advanced Solid Tumors, MTD Finding
Primary trial objective in this three arm trial is to assess the safety and tolerability of EMD 521873, and to determine whether the maximum tolerated dose (MTD) is reached with EMD 521873 doses of up to 1.5 mg/kg given alone or…
- Trial name
- NCT01032681
- Testing
- EMD 521873
- Where
- 5 sites in Germany, Switzerland
- Volunteers
- 66 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Acute Myeloid Leukemia
Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
The purpose of this study in AML patients is to test whether vadastuximab talirine (SGN-CD33A; 33A) combined with either azacitidine or decitabine improves remission rates and extends overall survival as compared to placebo…
- Trial name
- CASCADE (NCT02785900)
- Testing
- 33A, azacitidine, decitabine
- Where
- 128 sites in United States, Australia and 14 more
- Volunteers
- 240 people
- Sponsor
- Seagen Inc.
Triple-negative Breast Cancer
Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer
This study will look to establish the recommended biologic dose of AE37 in combination with pembrolizumab that will enhance the tumor-specific immune response and demonstrate efficacy in patients with advanced triple-negative…
- Trial name
- NSABP FB-14 (NCT04024800)
- Testing
- AE37 Peptide vaccine, Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 29 people
- Sponsor
- NuGenerex Immuno-Oncology
Advanced Solid Tumor
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BG-C0979 monotherapy or in combination with tislelizumab in participants with selected advanced solid…
- Trial name
- NCT07414836
- Testing
- BG-C0979, Tislelizumab
- Where
- 18 sites in United States, Australia and 2 more
- Volunteers
- 84 people
- Sponsor
- BeOne Medicines
Neoplasm
Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies
Primary Objectives: Phase 1: To characterize the safety and tolerability of isatuximab in combination with atezolizumab in participants with unresectable hepatocellular carcinoma (HCC), platinum-refractory recurrent/metastatic…
- Trial name
- NCT03637764
- Testing
- Isatuximab SAR650984, Atezolizumab
- Where
- 26 sites in United States, Belgium and 6 more
- Volunteers
- 107 people
- Sponsor
- Sanofi
Colorectal Neoplasms, Metastases, Neoplasm
Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma
This is a phase II, multicenter, target enrollment of 250 evaluable patients, open-label study of cetuximab in patients with refractory, metastatic colorectal carcinoma.
- Trial name
- NCT00044863
- Testing
- Erbitux (Cetuximab)
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Eli Lilly and Company
Pancreatic Cancer
Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if gemcitabine is more effective with or without exatecan mesylate in treating pancreatic…
- Trial name
- NCT00023972
- Testing
- exatecan mesylate, gemcitabine hydrochloride
- Where
- 74 sites in United States, Canada and 1 more
- Sponsor
- Daiichi Sankyo
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.